Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE Notably, the addition of trastuzumab to first-line chemotherapy has improved the overall survival of patients with HER2-positive gastric cancer, and has become the standard-of-care treatment for this group of patients. 31548601 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE Trastuzumab in combination with paclitaxel enhances antitumor activity by promoting apoptosis in human epidermal growth factor receptor 2-positive trastuzumab-resistant gastric cancer xenograft models. 31633500 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy. 31667572 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE Inhibitors of CMIP could be used as potential adjuvant therapeutic drugs for HER2 positive gastric cancer. 31822364 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE HER2-ECD (human epidermal growth factor receptor 2 - extracellular domain) is a prominent therapeutic target validated for treating HER2-positive breast and gastric cancer, but HER2-specific therapeutic options for treating advanced gastric cancer remain limited. 30365359 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE The treatment of patients with human epidermal growth factor receptor 2 (HER2)-negative gastric cancer is a major challenge. 31423245 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. 31587095 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE PD-L1 membrane expression on tumour cells (TC) and infiltrating immune cells (IC), CD3 + T-lymphocytes, CD8+ cytotoxic T-cells, ATM and HER2 were assessed by immunohistochemistry (IHC) in the ACRG (Asian Cancer Research Group) GC cohort (N = 380). 30729066 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 AlteredExpression disease BEFREE We aimed to evaluate whether HER2 expression in gastric cancer is affected by trastuzumab therapy. 30386954 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 AlteredExpression disease BEFREE In conclusion, intratumoral heterogeneity of HER2 expression is observed in 52% of metastatic GC cases. 31022472 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE We studied the plasma human epidermal growth factor receptor 2 (HER2) amplification in gastric cancer (GC) patients by droplet digital PCR (ddPCR) during therapy with trastuzumab. 30838039 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE Therefore, d16HER2 may be considered as a "flag" of HER2 dependence in GC and can be clinically investigated as a marker of trastuzumab susceptibility in several other HER2-driven cancers, including CRC. 30837627 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE Gastric cancer (GC) has also been slow to benefit from biomarker discovery and development and the successful utilisation of targeted therapies, with the exception of trastuzumab in HER2 positive cancers. 30597479 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE After phase III clinical trials, trastuzumab, anti-Erb-B2 receptor tyrosine kinase 2 (commonly known as ERBB2) and ramucirumab, anti-vascular endothelial growth factor receptor 2 (commonly known as VEGFR2) monoclonal antibodies, were approved and introduced into first- and second-line therapies for patients with advanced/metastatic GC. 31662821 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE The aim of our work was to address if pyrotinib treatment impacts the effect of HER2-positive GC cell-derived exosomes on endothelial cell (EC) progression. 31114227 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE Dual block HER2 assessment can effectively increase the HER2 positive rate in resected specimens of gastric cancer (GC). 31739285 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE <b>Introduction</b>: CT-P6 (trastuzumab-pkrb, Herzuma) is a trastuzumab biosimilar approved for use in HER2 positive breast cancer and HER2 positive gastric cancer. 31507219 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 GeneticVariation disease BEFREE The SNPs rs2643194, rs2934971, and rs1058808 of the ERBB2 gene were associated with increased risk for GC. 31116314 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE These findings provide the basis for investigating the regulation of MAPK signaling pathways by HER2 and potential therapeutic targets for inhibiting metastasis and invasion in GC. 29734245 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. 30927036 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE Trastuzumab, an anti-human epidermal growth factor type 2 (HER2) monoclonal antibody, is effective in HER2-positive stomach cancer. 29992451 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE We analyzed 25 cases of gastric cancer that received preoperative chemotherapy and selected the six pre-treatment samples that were HER2-positive. 30348707 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 GeneticVariation disease BEFREE Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. 30442682 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE Therapies targeting HER2 have improved clinical outcomes in HER2-positive breast and gastric cancers, and are emerging as potential treatments for HER2-positive metastatic colorectal cancer. 30857956 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.700 Biomarker disease BEFREE Although human epidermal growth factor receptor 2 (HER2) plays a prognostic and predictive role in breast and gastric cancer, its function in bladder cancer (BC) is still controversial. 30463072 2019